Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul:155:103456.
doi: 10.1016/j.jaut.2025.103456. Epub 2025 Jul 2.

STAT3 phosphorylation in the rheumatoid arthritis immunological synapse

Affiliations
Free article

STAT3 phosphorylation in the rheumatoid arthritis immunological synapse

Hila Novak-Kotzer et al. J Autoimmun. 2025 Jul.
Free article

Abstract

Targeting the JAK/STAT pathway has emerged as a key therapeutic strategy for managing Rheumatoid Arthritis (RA). JAK inhibitors suppress cytokine-mediated signaling, including the critical IL-6/STAT3 axis, thereby effectively targeting different aspects of the pathological process. However, despite their clinical efficacy, a subset of RA patients remains refractory to JAK inhibition, underscoring the need for alternative approaches. Here, we identify a novel JAK-independent mechanism of STAT3 activation, which is triggered by the formation of the immunological synapse (IS) in naive CD4+ T cells. Our data demonstrates that LCK mediates the TCR-dependent phosphorylation of STAT3 at the IS, highlighting this pathway as a previously unrecognized hallmark of early T cell activation. Furthermore, we show that the synaptic LCK/TCR-STAT3 pathway is compromised in RA. This discovery highlights a new therapeutic target for RA beyond JAK inhibitors, offering potential avenues for treating patients resistant to current therapies.

Keywords: CD4 T cells; Immunological synapse; JAK inhibitors; LCK; Rheumatoid arthritis; STAT3.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest This work was supported in part by a Research Agreement with Cue Biopharma for basic research on cytokine signaling pathways in the immunological synapse. AKJ and MLD are founders at Granza Bio. PCT has received research grants from Alphasigma and consultancy fees from Eli Lilly, Gilead, Alphasigma and AbbVie.

Update of

MeSH terms

Substances